SK Capital Is Said to Near Deal for Drug Distributor Swixx (1)

US private equity firm SK Capital Partners is nearing a deal to acquire Swiss drug distribution company Swixx Biopharma SA, according to people familiar with the matter.

The companies are poised to announce the transaction as soon as Monday, the people said, asking not to be identified as the information is private. A deal could value Swixx at about €1.5 billion ($1.8 billion), some of the people said. SK Capital has secured financing from alternative asset manager Ares, they added.

SK Capital has emerged as the likely buyer for Swixx after beating other industry players and private equity ...